Tiziana Life Sciences
June 18, 2025
Company Presentation
Multiple Therapeutics
153B
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
.png)
Company HQ City:
London
Company HQ State:
London
Company HQ Country:
United Kingdom
Year Founded:
2014
Lead Product in Development:
Foralumab
CEO
Ivor Elrifi
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
Exchange
NASDAQ
Ticker
TLSA
When you expect your next catalyst update?
Phase 2 Non-Active Secondary Progressive Multiple Sclerosis
What is your next catalyst (value inflection) update?
December 2025
Website
www.tizianalifesciences.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}